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Radical Transurethral Resection of the Prostate: 
A Possible Radical Procedure Against Localized 
Prostate Cancer with Almost No Postoperative 
Urinary Incontinence 
Masaru Morita and Takeshi Matsuura 
Kounaizaka Clinic, Matsubara Tokushukai Hospital 
Japan 
1. Introduction 
Current radical surgery against localized prostate cancer (PCa), such as open (Memmelaar, 
1949; Reiner & Walsh, 1979; Walsh & Donker, 1982), laparoscopic (Schuessler et al., 1997; 
Abbou et al., 2000; Guillonneau et al., 2003) or robot-assisted prostatectomy (Binder & 
Kramer, 2001; Menon et al., 2002; Menon et al., 2004), has a possible risk to injure supporting 
structures that surround and support the prostate as well as the external sphincter and the 
neurovascular bundle. As a result, postoperative stress urinary incontinence develops and 
continues in about 10 % of patients (Stanford et al., 2000; Lepor et al., 2004; Namiki et al., 
2009; Menon et al., 2007). Many procedures were introduced to improve the recovery of 
postoperative sexual function and urinary incontinence: bladder neck suspension or 
reconstruction (Poon et al., 2000), reconstruction of the rhabdosphincter (Rocco et al., 2007), 
periurethral suspension of the dorsal vein complex/urethral complex (Patel et al., 2009) and 
preservation of the neurovascular bundle (Kaiho et al., 2005), but have failed to solve the 
problems completely until now.  
The idea of a transurethral approach to resect almost total prostate tissues containing 
prostate cancer dates back to around 1990 (Valdivia Uría & López López, 1989; Reuter et al., 
1991). The technique did not significantly increase the operative morbidity and mortality 
compared with transurethral resection of the prostate (TURP) for benign prostate 
hyperplasia (BPH), and was suggested to be a valid alternative in some patients with 
prostate cancer. And a recent report concluded that localized prostate cancer could be 
resected transurethrally as radical as open surgery (Reuter et al., 2008). 
We thought that the transurethral approach to treat prostate cancer might bring better 
clinical results in the era of more improved resectoscope and more sensitive PSA test for 
the follow-up examination. We applied the transurethral technique to manage prostate 
cancer with the intention to eliminate almost all prostate tissues that contained localized 
cancer. As we already reported (Morita & Matsuura, 2009), radical transurethral resection 
of prostate cancer (RTUR-PCa) against localized prostate cancer has a possibility to 
minimize the injury to the external sphincter because an operator is able to recognize it 
clearly during the operation. With a minimal injury to the supporting structures of the 
prostate, we think that urinary continence can be reserved in RTUR-PCa at least at a 
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similar rate in transurethral resection of the prostate for BPH. Urinary incontinence after 
TURP is reported to occur in 0.4 – 3.3 % of the patients (Holtgrewe et al., 1989; AUA 
Practice Guidelines Committee, 2003). 
2. Patients and methods 
2.1 Patients 
Between December 2003 and December 2007, a total of 222 radical transurethral resection of 
prostate cancer were performed under spinal anesthesia in 170 patients with clinical stages 
of T1 or T2. Clinical stages were determined according to the UICC TNM staging system of 
1997. We informed the patients that the procedure was not a current standard radical 
method of management, and those who refused this procedure were excluded from the 
study. We also excluded patients with serious comorbidities that might affect their lives by 
standard TURP. Patients who gave a written informed consent were eligible for the study in 
the order they were given a diagnosis of localized prostate cancer. Institutional review 
board approved the TUR-PCa program after the preliminary study.  
Clinical stage was determined mainly by digital rectal examination and transrectal 
ultrasonography combined with the result of needle biopsy. We selected the patients to be 
checked for metastasis by eliminating patients with a minimum risk of metastasis according 
to Partin nomogram (Partin et al., 1993) and other reports on bone metastasis (Oesterling, 
1991; Oesterling, 1993). Ultrasound guided transrectal needle biopsy was performed on 123 
patients under caudal block, excluding the patients who were given a diagnosis of PCa after 
transurethral resection of the prostate for BPH. We obtained a total of 14 samples per case 
from the peripheral and transition zone including far lateral part, dividing the prostate into 
base (2 cores), upper middle part (2 cores), lower middle part (6 cores) and apex (4 cores), 
and we marked at the dorsal end.  
Patients ranged from 52 to 91 years old (mean ± SD: 72.9 ± 7.3, median: 74.0), preoperative 
PSA 1.5 to 100.5 ng/mL (mean ± SD: 10.38 ± 11.95, median: 6.2). Out of 170 patients, 20 
patients were lost to follow-up, leaving 150 patient included in this study. Clinical stages 
were as follows: T1b: 39 cases, T1c: 88 cases, T2: 23 cases. The present study includes the 
patients who were given a diagnosis of prostate cancer after TURP for BPH and on 
antiandrogen therapy. Thirty-five patients with a clinical stage of T1b were on oral 
antiandrogen (chlormadinone acetate) therapy for a mean period of 72.1 weeks with the 
longest case for 12 years preoperatively. In 11 patients with a clinical stage of T1c, oral 
antiandrogen was administered for the period between 5 and 47 months (mean 23.0 
months). In the other patients, oral antiandrogen was administered for 1 to 2 weeks just 
before RTUR-PCa, with no hormonal therapy being done after the operation. 
2.2 Operative procedures 
One authorized urologist (M.M.) performed all the operations. We used a standard TURP 
setup with an irrigation pressure of 80 cmH2O and an irrigation rate of 250 ml/min using 
D-sorbitol solution. After a rough resection of almost all the transition and central zone, 
we tried to resect and fulgurate the peripheral zone as completely as possible, especially 
where cancer was detected by biopsy. The resection was continued until adipose tissue, 
venous sinus or the external sphincter was identified. But we did not resect prostate 
tissues until adipose tissue was exposed all around the operative field. We aggressively 
fulgurated the area adjacent to where adipose tissue was exposed because the remaining 
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prostate tissue could be considered a thin layer. We especially paid attention not to 
distend the bladder too much to prevent a high irrigation pressure and a resultant TUR 
syndrome. Special attention was paid to avoid the injury to Santorini’s plexus and the 
rectum. The procedure was started from the 12 o’clock position, dividing the prostate into 
6 parts, and resected specimens were collected separately to examine the distribution of 
cancer. The seminal vesicle was partially resected at its attached part to the prostate 
between the 4 and 8 o’clock positions to determine the invasion of cancer. Finally the 
verumontanum was resected to achieve the complete resection of prostate tissue. A bag 
catheter was removed on the third postoperative day.  
 
 
 
 
Fig. 1. As radical TUR proceeds, adipose tissue and the external sphincter can be seen. 
2.3 Follow-up 
Postoperative PSA was measured every two months starting two months after the initial 
operation. PSA failure was diagnosed when PSA showed a consecutive rise over 0.2 ng/mL. 
This was also applied to the indication of the second RTUR-PCa. But when the PSA level 
reached a plateau between 0.2 and 1.0 ng/mL, we did not think immediately that the 
patients were in a treatment failure.  
3. Results 
3.1 Results of RTUR-PCa 
The mean follow up period of 150 patients was 45.1 ± 13.1 months (median: 43.9, range: 11 - 
72 months). The operation time ranged between 60 and 125 min. (mean 80 min.), and the 
resected tissue weight was between 4.0 and 63.0 grams (mean ± SD: 15.1 ± 8.5, median: 14.0). 
The preoperative mean PSA value was 9.4 ± 9.7 ng/mL (median: 6.0, range: 1.5 to 66.3), with 
an unknown value in one patient. Pathological stages were as follows: pT2a: 60 cases, pT2b: 
84, pT3: 5, pT4: 1 (Table 1). And Gleason score were: 4: 3 cases, 5: 7, 6: 35, 7: 67, 8: 17, 9: 21 
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(Table 2). Out of 20 patients who were lost to follow up, eight patients went for treatments 
elsewhere, five patients refused the second RTUR-PCa, and seven patients did not return to 
the clinic after their discharge. Three out of 8 patients who went to other hospitals 
underwent open radical prostatectomy. No malignant cells were detected pathologically in 
the residual prostate tissue in one patient, and no prostate tissue was found in the other two 
patients. Seven patients died during the follow-up period: three died of pneumonia, another 
of heart disease, of cerebrovascular accident, and of gastric cancer, and the last of biliary 
duct cancer, but there was no prostate cancer-related death. At present, ninety-seven 
patients have stable PSA after the first RTUR-PCa. 
 
 
Table 1. Results of RTUR-PCa grouped by pathological stage 
 
 
Table 2. Results of RTUR-PCa grouped by Gleason’s score 
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The second TUR-PCa was performed in 46 patients between 5 and 51 months (mean 16.8) 
after the first operation. The resected tissue weight was between 5.0 and 14.0 grams (mean ± 
SD: 6.6 ± 1.3, median: 6.0). No cancer cells were detected pathologically in 13 patients (28.3 
%). PSA failure was diagnosed in 9 patients who underwent the second RTUR-PCa. These 
patients showed high preoperative mean PSA value of 22.4 ng/mL (7.7 to 55.5 ng/mL) and 
PSA values did not fall significantly after the second RTUR-PCa. In the other 36 patents PSA 
levels stabilized after the second operation showing PSA雁0.01: 19 cases, 雁0.02: 4, 雁0.03: 2, 雁0.1: 7, 雁0.2: 1, 雁0.3: 1, 雁0.5: 2. 
3.2 Overall results 
PSA failure finally developed in 16 patients (10.7%) in the most recent follow-up. 
Preoperative PSA levels in these patients ranged from 7.3 to 55.5 ng/mL (mean 21.9), and 
Gleason scores were 7 in 8 patients, 8 in 2, and 9 in 6 (Table 1, 2). In the other 134 patients, 
PSA values stabilized as follows: PSA雁0.01: 55 cases, 雁0.02: 18, 雁0.03: 10, 雁0.04: 3, 雁0.1: 22, 雁0.2: 10, 雁0.7: 16.  
 
 
 
 
Fig. 2. Actuarial biochemical non-recurrence rate of each clinical stage 
In all cases studied, the actuarial biological non-recurrence rate for each clinical stage were 
as follows: T1b: 0.97 at 72 months, T1c: 0.92 at 66 months, T2: 0.65 at 64 months (Fig. 2). The 
actuarial biological non-recurrence rate for pT2a at 66 months and pT2b at 72 months were 
0.92 in both groups (Fig. 3). 
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Non-recurrence rate of each risk group according to D’Amico classification (D’Amico et.al, 
1998) are shown in Fig. 4. PSA failure did not develop in the low-risk group of 34 patients 
(stage T1c, T2a and PSA level雁10 ng/mL and Gleason score雁6). Biological non-recurrence 
rate was 91.4 % in the intermediate-risk group of 70 patients (stage T2b or Gleason score of 7 
or 10<PSA level雁20 ng/mL) and 78.3 % in the high-risk group of 46 patients (stage T2c or 
PSA level>20 ng/mL or Gleason score頑8) respectively. 
 
 
 
 
 
 
Fig. 3. Actuarial biochemical non-recurrence rate of each pathological stage (pT2a, solid line; 
pT2b, dotted line) 
3.3 Learning curve 
In some of the patients that underwent the first operation until March 2006, the PSA level 
did not show a sufficient drop. The operative technique became proficient and stable after 
that time, resulting in an acceptable clinical outcome (Fig. 5). Only 8 cases needed the 
second operation in 73 cases (p<0.0001 compared with cases before March 2006, chi 
square test) including 7 cases of PSA failure and 2 cases that was lost to follow-up, 
yielding more cases with lower PSA level as follows: PSA≤0.01: 31 cases, ≤0.02: 15, ≤0.03: 
4, ≤0.04: 2, ≤0.1: 8, ≤0.2: 4, ≤0.6: 3. Nadir PSA levels were 0.013 ± 0.026 ng/mL (median, 
0.004; range, 0.001-0.149 ng/mL) at 2.8 ± 1.4 months (median, 2; range, 2 - 8 months) 
postoperatively. 
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Fig. 4. Actuarial biological non-recurrence rate of each risk group 
 
 
 
Fig. 5. Latest PSA and the time of operation 
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3.4 Complications 
3.4.1 Urinary incontinence 
We evaluated stress urinary incontinence by asking patients the postoperative status of 
urinary leak on a cough or a sneeze and needs for a urinary pad. Urinary incontinence was 
seen in 35% of the patients when a bag catheter was removed on the third postoperative 
day. Incontinence soon improved until the third postoperative week, and no patients need a 
urinary pad at all at the third postoperative month.  
3.4.2 Other postoperative complications 
There were no patients in whom water intoxication developed or who needed 
transfusions perioperatively. Bladder neck contracture, which developed three to four 
months postoperatively, was the most frequent complication (49 cases, 32.7%). Other 
complications included pubic osteitis (2 cases), bladder tamponade (2 case), acute 
epididymitis (3 case), pulmonary embolism (1 case), and rectourethral fistula (1 case). 
Erectile function was preserved after the first operation in 26 (60.5%) of the evaluated 38 
sexually active patients. After the second operation only 1 out of 9 patients preserved 
erectile function probably due to the injury of the neurovascular bundle by excessive 
resection and fulguration during TUR-PCa. 
Figure 6 shows an urethrocystogram 3 weeks after the operation. The seminal vesicle is 
clearly visualized with no extravasation from the prostate bed. Marked expansion of the 
prostate bed may indicate that most prostate tissues were removed by the procedure. 
 
 
Fig. 6. Postoperative urethrocystogram (left anterior oblique)  
3.5 Focal TUR-PCa: Report of a case 
A 78-year–old man, who had a history of acute myocardial infarction and cerebral infarction 
and was on anticoagulation therapy, visited our clinic with a complaint of frequency with 
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urge incontinence. An estimated prostate volume was 33.0 cm3 by transrectal 
ultrasonography (TRUS). We started the treatment by giving alpha-blocker. His PSA at first 
visit was 4.20 ng/mL, and became slightly elevated to 5.47 ng/mL after two months. 
Transrectal prostate biopsy revealed prostate cancer confined in the right lobe. Gleason 
scores were 6 (3 + 3) in two out of 14 cores. He underwent standard TURP of the transition 
and central zone, and then we made a deeper resection of the peripheral zone of the right 
lobe. The operation took 80 minutes with no blood transfusion and water intoxication, and 
the resected weight was 27.0 g. A bag catheter was removed on the third postoperative day. 
The patient complained of mild dysuria that improved after two weeks, but did not 
complained of urinary incontinence. His erectile function had been lost preoperatively. 
Pathological examination confirmed prostate adenocarcinoma of Gleason score of 6 (3 + 3) 
in the right lobe. PSA values measured every two months were stable between 0.04 and 0.09 
ng/mL till 48 postoperative weeks. The PSA values indicate the efficacy of focal TUR-PCa 
though final evaluation of the treatment in this patient must need longer time.  
4. Discussions 
4.1 Radical TUR-PCa 
4.1.1 Results and complications 
Transurethral resection of the prostate is now ranked as a palliative therapy used mainly 
to relieve obstruction caused by prostate cancer. We advanced the transurethral technique 
and applied it to the complete ablation of prostate tissue (RTUR-PCa). Five and 10-year 
biochemical recurrence-free survival rates of radical prostatectomy are reported 70-84% 
(M. Han et al., 2003; Zincke et al., 1994; Catalona & Smith, 1994) and 52-82% (M. Han et 
al., 2003; Zincke et al., 1994; Catalona & Smith, 1994; Hull et al., 2002; Pound, 1997; Roehl, 
et al., 2004) respectively. Our result is comparable with that of radical prostatectomy, 
though the number of patients and the follow-up period are not sufficient to evaluate the 
procedure finally at this time.  
The operative technique may be more difficult than that of the standard TURP and needs 
more experience to become proficient. Extravasation of irrigation fluid is sure to occur 
during the operation, but no patients experienced water intoxication with the lowest 
irrigation pressure, and no patients needed blood transfusion. These suggest that the 
procedure can be performed safely. But much safer operation may be possible with the 
use of a bipolar TUR system. The postoperative course is usually uneventful and all 
patients could void immediately after the removal of indwelling catheters on the third 
postoperative day. Urinary incontinence was temporary, disappearing within 3 months. 
By the transurethral technique, continence can be reserved because the operator can easily 
detect the external sphincter, and supporting structures surrounding the prostate 
therefore allow the urethra to remain intact. The most excellent results of postoperative 
continence after radical prostatectomy are reported 93.0 % as to open prostatectomy 
(Walsh et al., 2000), 97.4 % as to laparoscopic surgery (Christopher et al., 2011) and 98.0 % 
as to robot-assisted surgery (Patel et al., 2005). And there seems no difference among the 
procedures when a surgeon becomes proficient. In the present study, the most frequent 
postoperative complication was bladder neck contracture, which had been expected 
because of an aggressive bladder neck resection to achieve radicality. But bladder neck 
contracture was easily treated by neck incision using an optical urethrotome under caudal 
block on a day surgery basis. 
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Dissemination of cancer cells may occur and affect the prognosis of patients. But the impact 
of TURP on the clinical outcome in patients with PCa is controversial (Levine et al., 1986; 
Zelefsky et al., 1993; Pansadoro et al., 1991). One report concludes that extensive TURP did 
not worsen the prognosis of patients with PCa (Trygg et al., 1998). 
The effect of chlormadinone acetate on postoperative PSA must be considered in the present 
study. We could not find any reports that describe the duration of the suppressive effect of 
chlormadinone acetate in patients with prostate cancer. But in patients with prostate 
hyperplasia given 50 mg/day of chlormadinone acetate for 16 weeks, PSA levels are 
reported to return to the baseline levels 16 weeks after discontinuation (Noguchi et al., 
2000). In this study the effect of preoperative hormonal therapy on the most recent PSA 
levels, therefore, can be minimum and negligible. 
4.1.2 PSA failure and the second RTUR-PCa 
In open or laparoscopic radical prostatectomy, residual cancer relates with PSA failure. RTUR-
PCa is probably less invasive than radical prostatectomy and more flexible in the point that the 
second operation can be indicated and easily done to eliminate residual cancer when PSA 
shows a successive rise. The second RTUR-PCa was required in 46 patients. But this is 
considered just a technical issue because the need for the second operation has decreased as 
the surgeon has become experienced. There were no malignancies reported by pathologists in 
13 out of 46 cases, although it is not clear whether cancer did not actually exist or missed to be 
detected in the specimens of the second operation. PSA failure is usually defined as a 
progressive rise over 0.2 ng/mL (Schild et al., 1996; Pound et al., 1999; Freedland et al., 2003). 
We took a careful watching policy if PSA level reached a plateau between 0.2 and 1.0 ng/mL, 
not regarding as PSA failure. But the second RTUR-PCa must be considered and easily 
performed when PSA levels start to rise continuously after the first operation. 
4.1.3 Some considerations to reduce urinary incontinence and erectile dysfunction 
We were able to obtain satisfactory postoperative PSA levels by RTUR-PCa comparable with 
open radical prostatectomy. But we recently started to think that, after a considerable 
number of the procedures, minimal residual prostate tissue at the part where cancer was not 
detected by biopsy might not necessarily prevent the radicality of the disease in carefully 
selected patients. We performed prostate biopsy to get information about the localization of 
cancer. The results of cancer localization from operative specimens were consistent with 
those from biopsy specimens in 46.7%. Information about the localization of cancer from 
biopsy specimens is very helpful to plan the manner of resection. Although an experienced 
resectionist can remove almost all prostate tissues transurethrally, aggressive resection can 
be applied where the cancer was detected by biopsy to achieve the radicality of the 
operation. Erectile function was preserved in about 60% of the patients in the present study. 
Preservation of the cavernous nerve can be achieved by leaving some prostate tissue not to 
be resected around the 4 or 8 o’clock position not to injure the nerve. When PSA levels rise 
postoperatively, removal of residual prostate tissue is possible by the second RTUR-PCa. 
Because the open radical prostatectomy is likely to damage the supporting tissue around the 
prostate and the urethra, improvement of urinary incontinence and erectile function after 
the operation remains limited (Stanford et al., 2000). RTUR-PCa, therefore, can provide 
urinary continence at least to the same degree as TURP for BPH. RTUR-PCa may be also a 
breakthrough to prevent the development of erectile dysfunction.  
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4.2 Focal TUR-PCa 
4.2.1 The idea of focal therapy for prostate cancer 
Currently, the two main options for the radical treatment of localized prostate cancer are 
radical prostatectomy (Memmelaar, 1949; Reiner & Walsh, 1979; Walsh & Donker, 
1982；Schuessler et al., 1997; Abbou et al., 2000; Guillonneau et al., 2003；Binder & 
Kramer, 2001; Menon et al., 2002; Menon et al., 2004) and irradiation therapy (Zelefsky et 
al., 2002; Wahlgren et al., 2007), but post-treatment morbidities that annoy the patients 
include urinary incontinence and erectile dysfunction as to operative therapy, and urinary 
frequency, difficult urination, erectile dysfunction and rectal hemorrhage as to irradiation 
therapy. On the other hand, active surveillance policy or watchful waiting, which is an 
ultimate non-invasive procedure, is also accepted to care for the patients with low risk 
cancer (Bill-Axelson et al., 2008; Wilt et al., 2009). But active surveillance seems still 
difficult in the point to select a suitable patient, and the patient may feel anxiety about 
cancer progression.  
4.2.2 Current options of focal therapy 
Recently introduced concept of focal ablative therapy (Moul et al., 2009; Polascik et al., 2008; 
Eggener et al., 2007) based on the accumulated pathological and clinical findings after radical 
prostatectomy, may be the third idea to treat patients with localized prostate cancer. Focal 
therapy may contribute to minimize morbidities such as incontinence or erectile dysfunction 
by trying to destruct minimum prostate tissues with cancer in it. The reported rate of 
postoperative urinary incontinence decreased as the improvement of equipment and 
technique as follows: 1 to 3 % in cryotherapy (Long et al., 1998; K.R. Han et al., 2003; Hubosky 
et al., 2007; Polascik et al., 2007; Dhar et al., 2010) and 0.8 % in HIFU (Uchida et al., 2009). 
The procedures are less invasive and repeatable, and other radical procedures can be 
applied when necessary after the focal therapy. One of the most important points at issue 
concerning the focal therapy lies in the selection of the most suitable candidate. Prostate 
cancer is often multifocal, and then the location of cancer must be properly diagnosed 
preoperatively. Because current imaging technique cannot detect a tiny focus of cancer, 
mapping biopsy technique is reported using a template (Onik & Barzell, 2008; Crawford et 
al., 2005; Furuno et al., 2004) to get information about the precise location of cancer focuses. 
Procedures of focal therapy, such as cryotherapy (Onik et al., 1993; Cohen et al., 1995; 
Zisman et al., 2001; Babaian et al., 2008) and high intensity focused ultrasound (HIFU) 
(Madersbacher et al., 1995; Thüroff et al., 2003; Poissonnier et al., 2007; Lee et al., 2006), are 
now still thought to be an experimental one in the point that the evaluation of the efficacy is 
still controversial because the standard of evaluation using PSA has not been established 
yet. The other serious drawback of these procedures is that we cannot obtain prostate 
tissues. The pathological evaluation is limited only to biopsy specimens, which may confuse 
the results to evaluate the procedure because pathological diagnosis by operation specimen 
is sometimes different from that by biopsy specimen.  
4.2.3 Advantages of transurethral resection 
We think transurethral resection as a focal therapy for localized prostate cancer has 
advantages over cryotherapy or HIHU. We can control the resection of prostate tissues 
precisely under direct vision. We can also obtain specimens for pathological examination. 
PSA is applied to the follow-up examination and there remains a possibility to carry out the 
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second TUR to aim at the radical treatment in case of PSA failure. In a patient with prostate 
cancer confined to one lateral lobe by biopsy, aggressive resection and fulguration can be 
done in the affected lobe, and appropriate non-radical resection can be applied in the other 
lobe only to check for cancer tissues (Morita & Matsuura, 2011). Control of prostate cancer, 
as a result, may be possible preserving urinary continence and erectile function. 
5. Conclusion 
Recent introduction of PSA into the health check up program in Japan resulted in a marked 
increase of patients with early stage prostate cancer. These patients were treated until now 
by open or laparoscopic prostatectomy, irradiation therapy including external beam 
irradiation and brachytherapy, hormonal therapy, watchful waiting and high intensity 
focused ultrasound. From the present study with the longest follow-up patients of 6 years, 
RTUR-PCa can be an effective treatment option for the radical treatment of prostate cancer, 
although the results of much longer follow up with more cases remain to be studied. 
To avoid the possibility of overdiagnosis and/or overtreatment, less invasive focal TUR-
PCa, can be also a suitable option of focal ablative therapy with less postoperative morbidity 
in carefully selected patients. 
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